MétaCan
Menu
← Back to cohort

S499 The Efficacy and Safety of Vonoprazan, a Potassium-Competitive Acid Blocker, for the Treatment of Proton-Pump Inhibitor-Resistant Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis

2023· review· en· W4387750109 on OpenAlexaboutno aff
Elvira Lesmana, Daniel Martin Simadibrata, Ronnie Fass

Bibliographic record

VenueThe American Journal of Gastroenterology · 2023
Typereview
Languageen
FieldMedicine
TopicGastroesophageal reflux and treatments
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineGERDInternal medicineNerdProton-pump inhibitorAdverse effectGastroenterologyMeta-analysisRefluxPharmacologyDisease

Abstract

fetched live from OpenAlex

Introduction: Up to 40% of Gastroesophageal Reflux Disease (GERD) patients experience inadequate symptom relief with Proton Pump Inhibitor (PPI), termed PPI-resistant or refractory GERD. Vonoprazan is a novel acid-suppressive medication (Potassium Competitive Acid Blocker) that inhibits the H+/K+ ATPase pump at the potassium binding site and has been shown to have better efficacy than a PPI in suppressing gastric acid secretion. This systematic review and meta-analysis summarize the efficacy and safety of Vonoprazan in the treatment of GERD (both erosive esophagitis [EE] and non-erosive reflux disease [NERD]. Methods: Four electronic databases (Medline, Embase, SCOPUS, and CENTRAL) were searched for studies indexed up to May 26, 2023. Both observational studies and clinical trials that assessed the efficacy and safety of Vonoprazan in PPI-resistant GERD, regardless of phenotypes, were included. Efficacy outcomes included healing and maintenance rates of EE and improvement of the Frequency Scale for the Symptoms of GERD (FSSG) scores. Safety outcomes were any adverse events (AE), drug-related AE, or serious AE (SAE). The modified Newcastle-Ottawa Scale (NOS) was used to assess study quality. The fixed-effect model was used to pool the efficacy and safety outcomes. Results: Fourteen studies were included in this systematic review. Only 1 study included double-dose, 2 had both standard-dose and double-dose, and the remaining included only standard-dose PPI-resistant GERD. Healing rates of PPI-resistant EE of Vonoprazan were 91.7% (95%CI 86.8-94.8%; n-study: 5; 176/192) at Week 4 and 82.1% (95%CI 63.6-92.4%; n-study: 4; 23/28) at Week 8. For healed PPI-resistant EE, the overall maintenance rates of Vonoprazan were 79.5% (95% 65.1-89.0%; n-study: 2; 35/44) at Week 8, 86.0% (95%CI 72.1-94.7%; n-study: 1; 37/43) at Week 24, and 87.9% (95%CI 77.6-93.8%; n-study: 2; 58/66) at Week 48. FSSG scores were improved in 74.6% (95%CI 65.8-81.7%; n-study: 2; 85/114) of the patients at Week 4 and 51.9% (95%CI 37.8-65.7%) at Week 8. Any AE, drug-related AE, and SAE of Vonoprazan were low to none in PPI-resistant GERD patients. Conclusion: Vonoprazan demonstrated high efficacy for healing and maintenance of PPI-resistant EE and moderate efficacy for improvement of FSSG score. Vonoprazan appears to be well tolerated in patients with PPI-resistant GERD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.011
metaresearch head score (Gemma)0.023
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.016
Threshold uncertainty score0.059

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0110.023
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0160.028
Bibliometrics0.0080.008
Science and technology studies0.0010.001
Scholarly communication0.0030.002
Open science0.0020.001
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0060.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.047
GPT teacher head0.352
Teacher spread0.304 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicGastroesophageal reflux and treatments→French-language works237,207→